Biofrontera Pharma GMBH

Biofrontera Pharma GMBH is a wholly-owned German subsidiary of Biofrontera AG, a publicly listed biopharmaceutical company traded on the Frankfurt Stock Exchange (Prime Standard). Headquartered in Leverkusen, Germany, Biofrontera AG was founded in 1997, with Biofrontera Pharma GMBH incorporated around 2004. As of May 31, 2026, the parent company, Biofrontera AG, had approximately 92 employees. The trailing 12-month revenue for Biofrontera (Pharmaceuticals) as of March 31, 2026, was $15.8 million, with an annual revenue of $41.71 million in 2025.

Biofrontera specializes in dermatology, focusing on the discovery, development, and distribution of pharmaceutical products, medical devices, and cosmetics. Biofrontera Pharma GMBH is responsible for the production, quality control, and licensing and marketing of the Biofrontera Group's products. Their primary product is Ameluz®, a topical prescription drug for photodynamic therapy (PDT) used to treat certain superficial skin cancers and their precursors, such as actinic keratosis. They also produce the BF-RhodoLED® and BF-RhodoLED XL lamps used in conjunction with Ameluz for PDT, and market dermocosmetic products like Belixos.

In terms of patent litigation, Biofrontera Pharma GMBH has a posture of actively asserting its patent rights or challenging competitor patents. The company is recorded as a plaintiff in one tracked case and has no defendant cases in the provided data. This singular tracked case, Biofrontera Pharma GMBH et al. v. Sun Pharmaceutical Industries Inc., commenced on August 21, 2024, at the Patent Trial and Appeal Board (PTAB). This aligns with public reports indicating Biofrontera has faced lawsuits from Sun Pharmaceuticals and has actively challenged Sun Pharma's patent claims, with the U.S. Patent Office finding some of Sun Pharma's patent claims unpatentable in February 2026.